260 related articles for article (PubMed ID: 31378574)
1. Effects of single and combined immunotherapy approach targeting amyloid β protein and α-synuclein in a dementia with Lewy bodies-like model.
Mandler M; Rockenstein E; Overk C; Mante M; Florio J; Adame A; Kim C; Santic R; Schneeberger A; Mattner F; Schmidhuber S; Galabova G; Spencer B; Masliah E; Rissman RA
Alzheimers Dement; 2019 Sep; 15(9):1133-1148. PubMed ID: 31378574
[TBL] [Abstract][Full Text] [Related]
2. Human amyloid beta and α-synuclein co-expression in neurons impair behavior and recapitulate features for Lewy body dementia in Caenorhabditis elegans.
Huang X; Wang C; Chen L; Zhang T; Leung KL; Wong G
Biochim Biophys Acta Mol Basis Dis; 2021 Oct; 1867(10):166203. PubMed ID: 34146705
[TBL] [Abstract][Full Text] [Related]
3. Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases.
Sengupta U; Kayed R
Prog Neurobiol; 2022 Jul; 214():102270. PubMed ID: 35447272
[TBL] [Abstract][Full Text] [Related]
4. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA
Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090
[TBL] [Abstract][Full Text] [Related]
5. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM
Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088
[TBL] [Abstract][Full Text] [Related]
6. α-Synuclein Heteromers in Red Blood Cells of Alzheimer's Disease and Lewy Body Dementia Patients.
Daniele S; Baldacci F; Piccarducci R; Palermo G; Giampietri L; Manca ML; Pietrobono D; Frosini D; Nicoletti V; Tognoni G; Giorgi FS; Lo Gerfo A; Petrozzi L; Cavallini C; Franzoni F; Ceravolo R; Siciliano G; Trincavelli ML; Martini C; Bonuccelli U
J Alzheimers Dis; 2021; 80(2):885-893. PubMed ID: 33579836
[TBL] [Abstract][Full Text] [Related]
7. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
[TBL] [Abstract][Full Text] [Related]
8. Quantifying regional α -synuclein, amyloid β, and tau accumulation in lewy body dementia.
Miller RL; Dhavale DD; O'Shea JY; Andruska KM; Liu J; Franklin EE; Buddhala C; Loftin SK; Cirrito JR; Perrin RJ; Cairns NJ; Campbell MC; Perlmutter JS; Kotzbauer PT
Ann Clin Transl Neurol; 2022 Feb; 9(2):106-121. PubMed ID: 35060360
[TBL] [Abstract][Full Text] [Related]
9. Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5--implications for dementia with Lewy bodies.
Overk CR; Cartier A; Shaked G; Rockenstein E; Ubhi K; Spencer B; Price DL; Patrick C; Desplats P; Masliah E
Mol Neurodegener; 2014 May; 9():18. PubMed ID: 24885390
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.
Valera E; Spencer B; Masliah E
Neurotherapeutics; 2016 Jan; 13(1):179-89. PubMed ID: 26494242
[TBL] [Abstract][Full Text] [Related]
11. Lewy- and Alzheimer-type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum.
Sierra M; Gelpi E; Martí MJ; Compta Y
Neuropathol Appl Neurobiol; 2016 Aug; 42(5):451-62. PubMed ID: 26810462
[TBL] [Abstract][Full Text] [Related]
12. Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies.
Rockenstein E; Ostroff G; Dikengil F; Rus F; Mante M; Florio J; Adame A; Trinh I; Kim C; Overk C; Masliah E; Rissman RA
J Neurosci; 2018 Jan; 38(4):1000-1014. PubMed ID: 29246926
[TBL] [Abstract][Full Text] [Related]
13. Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In Vitro.
Köppen J; Schulze A; Machner L; Wermann M; Eichentopf R; Guthardt M; Hähnel A; Klehm J; Kriegeskorte MC; Hartlage-Rübsamen M; Morawski M; von Hörsten S; Demuth HU; Roßner S; Schilling S
Molecules; 2020 Jan; 25(3):. PubMed ID: 32013170
[TBL] [Abstract][Full Text] [Related]
14. Amyloid-Beta (Aβ) Plaques Promote Seeding and Spreading of Alpha-Synuclein and Tau in a Mouse Model of Lewy Body Disorders with Aβ Pathology.
Bassil F; Brown HJ; Pattabhiraman S; Iwasyk JE; Maghames CM; Meymand ES; Cox TO; Riddle DM; Zhang B; Trojanowski JQ; Lee VM
Neuron; 2020 Jan; 105(2):260-275.e6. PubMed ID: 31759806
[TBL] [Abstract][Full Text] [Related]
15. Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease.
Mandal PK; Pettegrew JW; Masliah E; Hamilton RL; Mandal R
Neurochem Res; 2006 Sep; 31(9):1153-62. PubMed ID: 16947080
[TBL] [Abstract][Full Text] [Related]
16. Cerebral inoculation of human A53T α-synuclein reduces spatial memory decline and amyloid-β aggregation in APP/PS1 transgenic mice of Alzheimer's disease.
Hao YN; Lu QX; Zhai YH; Wang HY; Wu MN; Hu MM; Yang B; Wang ZJ; Wu ZW; Qi JS
Brain Res Bull; 2018 Oct; 143():116-122. PubMed ID: 30366065
[TBL] [Abstract][Full Text] [Related]
17. Neuronal TNFα, Not α-Syn, Underlies PDD-Like Disease Progression in IFNβ-KO Mice.
Villanueva EB; Tresse E; Liu Y; Duarte JN; Jimenez-Duran G; Ejlerskov P; Kretz O; Loreth D; Goldmann T; Prinz M; Issazadeh-Navikas S
Ann Neurol; 2021 Nov; 90(5):789-807. PubMed ID: 34476836
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human α-synuclein: feasibility study.
Ghochikyan A; Petrushina I; Davtyan H; Hovakimyan A; Saing T; Davtyan A; Cribbs DH; Agadjanyan MG
Neurosci Lett; 2014 Feb; 560():86-91. PubMed ID: 24361548
[TBL] [Abstract][Full Text] [Related]
19. The limbic and neocortical contribution of α-synuclein, tau, and amyloid β to disease duration in dementia with Lewy bodies.
Ferman TJ; Aoki N; Crook JE; Murray ME; Graff-Radford NR; van Gerpen JA; Uitti RJ; Wszolek ZK; Graff-Radford J; Pedraza O; Kantarci K; Boeve BF; Dickson DW
Alzheimers Dement; 2018 Mar; 14(3):330-339. PubMed ID: 29100980
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.
Valera E; Masliah E
Pharmacol Ther; 2013 Jun; 138(3):311-22. PubMed ID: 23384597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
